目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术...目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术前1周内进行了18F-F DG P ET/CT显像检查,并在术后3~6个月内进行了复查,监测复发或转移情况。术前的TNM分期和术后的复发转移情况均以手术病理结果或临床随访结果为金标准进行评估。结果术前分期诊断中,18F-FD(G P ET/CT显像的T分期、N分期和M分期的符合率分别为86.59%、81.93%和100%,一致性检验Kappa值分别为0.834、0.793和1.000。术后的复发转移检测中,18F-FDG PET/CT显像在术后6个月内成功检出了22例(88.00%)的复发转移病例,其诊断灵敏度为88.00%,特异度为100.00%。结论18F-FDG PET/CT显像在肺癌术前分期以及术后复发转移的预测中具有较高的准确性和可靠性,该方法可以为临床提供有效的参考信息,有助于医生制定更准确的治疗方案和更有效的随访策略。展开更多
Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (N...Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (NSCLC). <sup>18</sup>F-FDG PET/CT, as a noninvasive and effective examination technique, reflects the location and functional information of tumor lesions through the metabolic level of glucose. Studies have shown that PD-L1 may affect the sugar metabolism of tumor cells. Therefore, <sup>18</sup>F-FDG PET/CT can be used to predict the expression of PD-L1 and evaluate the efficacy of immunotherapy. This article mainly introduces the relationship between PD-L1 expression and NSCLC, the advantages of <sup>18</sup>F-FDG PET/CT, the imaging mechanism of <sup>18</sup>F-FDG PET/CT based on PD-L1 and its research progress in NSCLC, and the role of <sup>18</sup>F-FDG PET/CT in the response and efficacy evaluation of immunotherapy in NSCLC, aiming to provide a reference for the clinic.展开更多
Background: The PET/CT imaging studies have two doses components the dose from the PET radiopharmaceutical and the other from the low dose CT used for PET images attenuation correction. We have one PET/CT scanner at o...Background: The PET/CT imaging studies have two doses components the dose from the PET radiopharmaceutical and the other from the low dose CT used for PET images attenuation correction. We have one PET/CT scanner at our institution a Philips Time of Flight scanner. Our local patient’s radiation protection rules requires continuous assessment of radiation doses delivered to our patients. Purposes: The objectives of this study are to develop a weight- based facility DRLs for paediatric F-18-FDG PET-CT imaging for oncology in a large tertiary hospital and to determine whether the calculated DRLs compares with internationally published DRLs. Materials & Methods: Radiation dose data and patient demographics of two-hundreds and sixteen paediatric PET-CT oncology patients imaging procedures from one large tertiary hospital were selected and analysed in order to establish a facility paediatric DRLs. Statistical analysis was performed. Results: The PET dose reference levels ranged between [62 - 525] MBq of injected activity for a range of pediatric age groups. The CTDI<sub>vol</sub> values were between 3.5 and 16.5 mGy for all age groups. Comparison with current EANM and SNMMI recommendations of patient’s dose are discussed. Conclusion: Our pediatric PET/CT reference levels are higher than the ones reported internationally with notable variations. .展开更多
文摘目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术前1周内进行了18F-F DG P ET/CT显像检查,并在术后3~6个月内进行了复查,监测复发或转移情况。术前的TNM分期和术后的复发转移情况均以手术病理结果或临床随访结果为金标准进行评估。结果术前分期诊断中,18F-FD(G P ET/CT显像的T分期、N分期和M分期的符合率分别为86.59%、81.93%和100%,一致性检验Kappa值分别为0.834、0.793和1.000。术后的复发转移检测中,18F-FDG PET/CT显像在术后6个月内成功检出了22例(88.00%)的复发转移病例,其诊断灵敏度为88.00%,特异度为100.00%。结论18F-FDG PET/CT显像在肺癌术前分期以及术后复发转移的预测中具有较高的准确性和可靠性,该方法可以为临床提供有效的参考信息,有助于医生制定更准确的治疗方案和更有效的随访策略。
文摘Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (NSCLC). <sup>18</sup>F-FDG PET/CT, as a noninvasive and effective examination technique, reflects the location and functional information of tumor lesions through the metabolic level of glucose. Studies have shown that PD-L1 may affect the sugar metabolism of tumor cells. Therefore, <sup>18</sup>F-FDG PET/CT can be used to predict the expression of PD-L1 and evaluate the efficacy of immunotherapy. This article mainly introduces the relationship between PD-L1 expression and NSCLC, the advantages of <sup>18</sup>F-FDG PET/CT, the imaging mechanism of <sup>18</sup>F-FDG PET/CT based on PD-L1 and its research progress in NSCLC, and the role of <sup>18</sup>F-FDG PET/CT in the response and efficacy evaluation of immunotherapy in NSCLC, aiming to provide a reference for the clinic.
文摘Background: The PET/CT imaging studies have two doses components the dose from the PET radiopharmaceutical and the other from the low dose CT used for PET images attenuation correction. We have one PET/CT scanner at our institution a Philips Time of Flight scanner. Our local patient’s radiation protection rules requires continuous assessment of radiation doses delivered to our patients. Purposes: The objectives of this study are to develop a weight- based facility DRLs for paediatric F-18-FDG PET-CT imaging for oncology in a large tertiary hospital and to determine whether the calculated DRLs compares with internationally published DRLs. Materials & Methods: Radiation dose data and patient demographics of two-hundreds and sixteen paediatric PET-CT oncology patients imaging procedures from one large tertiary hospital were selected and analysed in order to establish a facility paediatric DRLs. Statistical analysis was performed. Results: The PET dose reference levels ranged between [62 - 525] MBq of injected activity for a range of pediatric age groups. The CTDI<sub>vol</sub> values were between 3.5 and 16.5 mGy for all age groups. Comparison with current EANM and SNMMI recommendations of patient’s dose are discussed. Conclusion: Our pediatric PET/CT reference levels are higher than the ones reported internationally with notable variations. .
